COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC

被引：0
|
作者：
Dolezal, T. [1 ]
Skoupa, J. [2 ]
Taylor, M. J. [3 ]
Whitehead, S. [3 ]
Rausova, V [4 ]
Pavlikova, P. [4 ]
机构：
[1] Charles Univ Prague, Prague, Czech Republic
[2] Pharma Projects, Prague, Czech Republic
[3] Univ York, York YO10 5DD, N Yorkshire, England
[4] GlaxoSmithKline Inc, Prague, Czech Republic
来源：
VALUE IN HEALTH | 2008年 / 11卷 / 06期
关键词：
D O I：
10.1016/S1098-3015(10)66674-0
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A504 / A504
页数：1
相关论文
共 50 条
  • [1] Cost-effectiveness of Rosiglitazone Combination Therapy for the Treatment of Type 2 Diabetes Mellitus in the UK
    Sophie Beale
    Adrian Bagust
    Arran T. Shearer
    Alan Martin
    Lisa Hulme
    [J]. PharmacoEconomics, 2006, 24 (Suppl 1) : 21 - 34
  • [2] Cost-effectiveness of rosiglitazone oral combination for the treatment of type 2 diabetes in Germany
    Shearer A.T.
    Bagust A.
    Liebl A.
    Schoeffski O.
    Goertz A.
    [J]. PharmacoEconomics, 2006, 24 (Suppl 1) : 35 - 48
  • [3] Cost-effectiveness of liraglutide versus rosiglitazone, both in combination with glimepiride in treatment of type 2 diabetes in the US
    Lee, W. C.
    Conner, C.
    Hammer, M.
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2011, 27 (05) : 897 - 906
  • [4] Lifetime cost-effectiveness of rosiglitazone/metformin fixed dose combination for the treatment of type 2 diabetes in Portugal
    Taylor, M.
    Shearer, A.
    Bagust, A.
    Vaz, J. P.
    Pereira, J.
    [J]. DIABETES, 2006, 55 : A548 - A548
  • [5] Lifetime health consequences and cost-effectiveness of rosiglitazone in combination with metformin for the treatment of type 2 diabetes in Spain
    Shearer A.T.
    Bagust A.
    Ampudia-Blasco F.J.
    Álvarez B.M.-L.
    Escolano I.P.
    París G.
    [J]. PharmacoEconomics, 2006, 24 (Suppl 1) : 49 - 59
  • [6] Cost-effectiveness in Germany of rosiglitazone-metformin combination in Type 2 diabetes.
    Bagust, A
    Shearer, A
    Schoeffski, O
    Reitberger, U
    Goertz, A
    Behrens, M
    [J]. DIABETOLOGIA, 2003, 46 : A444 - A444
  • [7] Cost-effectiveness of rosiglitazone-metformin combination in overweight patients with type 2 diabetes in Germany
    Shearer, A
    Bagust, A
    Schoeffski, O
    Reitberger, U
    Goertz, A
    Behrens, M
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 607 - 607
  • [8] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Milan Kvapil
    Martin Prázný
    Pavel Holik
    Karel Rychna
    Barnaby Hunt
    [J]. Diabetes Therapy, 2017, 8 : 1331 - 1347
  • [9] Cost-Effectiveness of IDegLira Versus Insulin Intensification Regimens for the Treatment of Adults with Type 2 Diabetes in the Czech Republic
    Kvapil, Milan
    Prazny, Martin
    Holik, Pavel
    Rychna, Karel
    Hunt, Barnaby
    [J]. DIABETES THERAPY, 2017, 8 (06) : 1331 - 1347
  • [10] Clinical and cost-effectiveness of Rosiglitazone-Metformin combination in patients with Type-2 Diabetes in Spain
    Shearer, A
    Bagust, A
    Ampudia-Blasco, J
    Martinez-Lage, B
    [J]. DIABETES, 2004, 53 : A293 - A293
12345